The Lancet Diabetes & Endocrinology
Papers 1437
1 page of 144 pages (1,437 results)
#1Oana Onisie (University of Otago)
#2Hamish Crocket (University of Waikato)H-Index: 5
Last.Martin de Bock (University of Otago)H-Index: 9
view all 0 authors...
#1Ildiko Lingvay (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
#2Andrei-Mircea Catarig (Novo Nordisk)
Last.Rory J. McCrimmon (Dund.: University of Dundee)H-Index: 34
view all 9 authors...
Summary Background Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (a...
#1Fereidoun Azizi (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 60
#2Farzad Hadaegh (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 26
Last.Mojtaba Lotfaliany (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 6
view all 0 authors...
Summary The Middle East and north Africa are home to different populations with widely varying cultures, histories, and socioeconomic settings. Hence, their health status, health management, and access to appropriate health care differ accordingly. In this Review, we examine data on the historical and prospective status of metabolic diseases in this region including obesity, diabetes, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. Women in the Middle East and north Africa ha...
#1Maria Fleseriu (OHSU: Oregon Health & Science University)H-Index: 21
#2Rosario PivonelloH-Index: 61
Last.Fredric CohenH-Index: 1
view all 11 authors...
Summary Background Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome. We aimed to investigate the efficacy and safety of levoketoconazole in patients with endogenous Cushing's syndrome. Methods SONICS is a phase 3, multicentre, open-label, non-randomised, single-arm study in which we recruited adults (≥18 years) with confirmed Cushing's syndrome and a mean...
#1Ankit Garg (U of T: University of Toronto)H-Index: 6
#2Vinay Garg (U of T: University of Toronto)H-Index: 1
Last.Gary F. Lewis (U of T: University of Toronto)H-Index: 46
view all 4 authors...
Summary Diagnostic scoring systems for familial hypercholesterolaemia and familial chylomicronaemia syndrome often cannot differentiate between adults who have extreme dyslipidaemia based on a simple monogenic cause versus people with a more complex cause involving polygenic factors and an environmental component. This more complex group of patients carries a substantial risk of atherosclerotic cardiovascular disease in the case of marked hypercholesterolaemia and pancreatitis in the case of mar...
#1Brendon L. Neuen (The George Institute for Global Health)H-Index: 5
#2Tamara K. Young (The George Institute for Global Health)H-Index: 1
Last.Clare Arnott (USYD: University of Sydney)H-Index: 4
view all 13 authors...
Summary Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or transplantation or death due to kidney disease, is uncertain. Additionally, previous studies have been underpowered to robustly assess heterogeneity of effects on kidney outcomes by different levels of estimated glomerular filtration rate (eGFR) and albuminuria. We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors ...